Can-Fite BioPharma Ltd. (TASE:CFBI) today announced successful interim results in its Phase I/II clinical trial to test the safety profile and efficacy of its CF-102 drug for liver cancer.
The trial included 18 patients, most of whom had previously taken Nexavar, made by Bayer AG (DAX: BAYN), to no avail.
Can-Fite said that CF-102 was found to be exceptionally safe at all dosages for patients with initial liver tumors and patients with first and second degree cirrhosis of the liver. The patients' median survival time was 8.1 months, which the company says is highly significant since CF-102 was given as a second line of therapy for most patients and because in some cases the cirrhosis was advanced.
The company is continuing to monitor patients still receiving CF-102. It will publish the final results of the trial later.
Can-Fite's share price rose 3.6% in morning trading today to NIS 0.87, giving a market cap of NIS 200 million.
Published by Globes [online], Israel business news - www.globes-online.com - on May 11, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011